214 related articles for article (PubMed ID: 35191982)
1. Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Lahu S; Ndrepepa G; Neumann FJ; Menichelli M; Bernlochner I; Richardt G; Wöhrle J; Witzenbichler B; Hemetsberger R; Mayer K; Akin I; Cassese S; Gewalt S; Xhepa E; Kufner S; Valina C; Sager HB; Joner M; Ibrahim T; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):687-694. PubMed ID: 35191982
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
Behnes M; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Akin I
Clin Res Cardiol; 2023 Apr; 112(4):518-528. PubMed ID: 35789430
[TBL] [Abstract][Full Text] [Related]
3. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial.
Gewalt S; Lahu S; Ndrepepa G; Pellegrini C; Bernlochner I; Neumann FJ; Menichelli M; Morath T; Witzenbichler B; Wöhrle J; Hoppe K; Richardt G; Laugwitz KL; Schunkert H; Kastrati A; Schüpke S; Mayer K
J Atheroscler Thromb; 2022 May; 29(5):747-761. PubMed ID: 33867409
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
[TBL] [Abstract][Full Text] [Related]
6. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
[TBL] [Abstract][Full Text] [Related]
7. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
8. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
9. The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes.
Aytekin A; Coughlan JJ; Ndrepepa G; Cassese S; Lahu S; Kufner S; Mayer K; Xhepa E; Gewalt S; Joner M; Hapfelmeier A; Angiolillo DJ; Menichelli M; Richardt G; Neumann FJ; Schunkert H; Kastrati A
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):231-239. PubMed ID: 36434779
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Spoendlin J; Gagne JJ; Lewey JJ; Patorno E; Schneeweiss S; Desai RJ
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1361-1370. PubMed ID: 30379372
[TBL] [Abstract][Full Text] [Related]
11. Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial.
Lahu S; Scalamogna M; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Neumann FJ; Kastrati A; Cassese S
J Am Heart Assoc; 2022 Dec; 11(24):e027257. PubMed ID: 36515247
[TBL] [Abstract][Full Text] [Related]
12. Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Koch T; Lahu S; Coughlan JJ; Cassese S; Voll F; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Angiolillo DJ; Sibbing D; Kastrati A; Kufner S
Thromb Haemost; 2023 Apr; 123(4):464-477. PubMed ID: 36442805
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
14. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
15. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes.
Lahu S; Ndrepepa G; Gewalt S; Schüpke S; Pellegrini C; Bernlochner I; Aytekin A; Neumann FJ; Menichelli M; Richardt G; Cassese S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Mayer K
Int J Cardiol; 2021 Sep; 338():8-13. PubMed ID: 34126130
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk.
Lahu S; Presch A; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Hapfelmeier A; Kufner S; Rifatov N; Sager HB; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Neumann FJ; Sibbing D; Angiolillo DJ; Kastrati A; Cassese S
Circ Cardiovasc Interv; 2022 Oct; 15(10):e012204. PubMed ID: 36256695
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
Lahu S; Behnes M; Ndrepepa G; Neumann FJ; Sibbing D; Bernlochner I; Menichelli M; Mayer K; Richardt G; Gewalt S; Angiolillo DJ; Coughlan JJ; Aytekin A; Witzenbichler B; Hochholzer W; Cassese S; Kufner S; Xhepa E; Sager HB; Joner M; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A; Akin I
Rev Esp Cardiol (Engl Ed); 2022 Sep; 75(9):747-755. PubMed ID: 34961732
[TBL] [Abstract][Full Text] [Related]
20. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
